Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Cancer Res. 2017 Apr 12;77(11):2927–2937. doi: 10.1158/0008-5472.CAN-16-3351

Figure 5.

Figure 5

Effects of small molecule inhibitors and anti-cancer agents on mCDS. A, In vitro growth inhibition of mCDS (mCDS 4, 15 and 16) cell lines by palbociclib, vandetanib and ABT199. Human clear cell sarcoma (KAS) and human osteosarcoma (U2OS) cell lines were also tested. Cells were treated with each reagent at the indicated concentration for 48 hours. The experiment was performed in triplicate, and average suppression rates with SEM, and IC50 are indicated. B, In vitro growth inhibition of mCDS and ES cell lines by bortezomib and trabectedin as in A. C, Growth inhibitory effects of bortezomib and palbociclib for mCDS in vivo. mCDS 16 cells were transplanted subcutaneously into nude mice, and tumor volume was measured every other day. Mean tumor volumes ± SEM for 5 mice of each group are plotted. The treatment times of trabectedin and palbociclib are indicated as arrows. *p < 0.01, **p < 0.001.